Results

RELiZORB is Specifically Designed to Deliver More Absorbable Calories from Enteral Formula

In controlled studies using a well-established porcine model of exocrine pancreatic insufficiency, RELiZORB increased plasma levels of omega-3 fats (DHA and EPA).

Formula hydrolyzed with RELiZORB was associated with a statistically significant increase in total fat absorption and improvement in uptake of omega-3 fatty acids (DHA and EPA) in plasma level over 24-hours compared with non-hydrolyzed formula without Relizorb (p<0.05).*

RELiZORB use increased plasma levels of omega-3 (DHA and EPA) in preclinical studies.

RELiZORB normalized plasma levels of DHA and EPA in a controlled study using a well-established porcine model of exocrine pancreatic insufficiency as seen in the figure below.

*The clinical significance of these observations has not been determined.

RELiZORB use enhanced fat absorption and caloric intake in preclinical studies as demonstrated by improved plasma levels of DHA and EPA over 12 days.*

 

*Studies performed in a porcine model of exocrine pancreatic insufficiency. The clinical significance of these observations has not been determined.

Higher levels of of fat-soluble vitamins (D and E) were observed with use of RELiZORB after 12 days.*

*Studies performed in a porcine model of exocrine pancreatic insufficiency. The clinical significance of these observations has not been determined.

RELiZORB hydrolyzes available fats in enteral formula.         

RELiZORB increases absorbable calories by hydrolyzing greater than 90% of available fats in most enteral formulas tested, including both long-chain triglycerides (LCTs) and medium-chain triglycerides (MCTs).

 *Representative results of in vitro testing with RELiZORB. The clinical significance of these observations has not been determined. 

Proven fat hydrolysis with RELiZORB across a range of enteral formulas.

In most enteral formulas tested, RELiZORB hydrolyzes >90% of available fats into readily absorbable fatty acids and monoglycerides.

Using 500 mL of formula with a pump rate of 120 mL/hr.

Note: Formula manufacturers may change the composition of their formulas, which may affect the operation of RELiZORB. Please refer to formula product websites for recent product descriptions, ingredients, and nutritional information. If you have questions about whether your formula can be used with RELiZORB, please contact RELiZORB Support Services at 1-844-RELiZORB (1-844-735-4967).

When Fats Are Not Hydrolyzed and Absorbed

  • Without the ability to properly hydrolyze available fats, patients may experience incomplete hydrolysis of fats, in particular long-chain triglycerides (LCTs), from enteral feeding, which can lead to fewer calories, weight loss, shortage of key fats, and lower levels of some vitamins
  • If fats are not hydrolyzed, patients may experience stomach pain, gas, and oily or foul smelling stools

Read more on fat malabsorption here.